Clinical data confirming real-world efficacy

Target group

People with asthma, chronic bronchitis, and persistent cough.

Primary objective

Relief and reduction in the time to change in intensity or resolution of cough and phlegm.

Key outcome

50% reduction in cough intensity already in 10 days. Significant loosening of phlegm in an average of 18 days.

Target group

Evaluation of efficacy in people with rheumatism, osteoarthritis, and gout.

Primary objective

Relief of symptoms, reduction in the need for analgesics.

Key outcome

After Month 1, relief and a reduction in the need for analgesics were observed in 66% of people.

Target group

Evaluation of efficacy in people with neuropathy (including people with diabetes), carpal tunnel syndrome, herniated intervertebral disc, and sciatic nerve compression.

Primary objective

Relief of symptoms and improvement in sensitivity and mobility of the limbs and spine.

Key outcome

Alleviation of symptoms within 14–19 days, improvement in mobility on average within 13–30 days depending on condition and severity, overall improvement in quality of life in 91% of participants.

Target group

Evaluation of efficacy as an adjunct to treatment in men with BPH (benign prostatic hyperplasia) and prostate cancer, and in women with HPV or abnormal (cancerous) cytology findings of the cervix.

Primary objective

Changes in PSA levels, prostate status (ultrasound), and cytology in women.

Key outcome

Additional PSA reduction of 14–27% after 3 months of use, clinical improvement (ultrasound) of the prostate, reduction in the number of night-time urinations by half, improvement in cytological findings in 2/3 of women.

Target group

Evaluation of efficacy in people with signs of tinnitus (ringing in the ears) or vertigo (dizziness).

Primary objective

Reduction in the intensity of auditory symptoms in the ear and the number of dizziness episodes.

Key outcome

Alleviation of unbearable auditory symptoms to a tolerable level in 20% of people after just 1 month of use, significant decrease in dizziness within a week.

Target group

Evaluation of efficacy in people with IBS, HIT, flatulence, bowel movement disorders, and intestinal cramps.

Primary objective

Changes in symptoms, relief, changes in bowel movement, change in quality of life.

Key outcome

Significant alleviation of symptoms on average as early as 8 days, flatulence -42%, number of bowel movements per day -26%, diet variety +24%, good response in up to 98% of people.

Target group

Evaluation of the effect in people with burnout syndrome, chronic stress, anxiety symptoms, or nervousness and restlessness.

Primary objective

Time to relief of anxiety symptoms, feelings of exhaustion, and restlessness.

Key outcome

Significant mental improvement was achieved on average within 17–21 days, when added to existing antidepressant therapy.